Clinical Trial Update: A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial comparing MB12, a proposed pembrolizumab biosimilar, to Keytruda in non-small cell lung cancer to assess pharmacokinetics, efficacy, safe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• MB12

Snippet

Sponsor: mAbxience Research S.L. | Conditions: Non Squamous Non Small Cell Lung Cancer | Phase 3 | Status: RECRUITING